FHL1 Overexpression as A Inhibitor of Lung Cancer Cell Invasion via Increasing RhoGDIß mRNA Expression

Document Type : Original Article


Department of Thoracic Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, PR. China


Objective: Four and a half Lin-11, Isl-1, Mac-3 (LIM) protein 1 (FHL1) is one of the FHL protein family, which is regarded as a tumor suppressor in the multiple malignant tumors. In this study, we aimed to explore the regulatory effects and mechanisms of FHL1 on lung cancer cell invasion.
Materials and Methods: In this experimental study, bioinformatics analysis of FHL1 transcripts in human lungadenocarcinomas of TCGA database was performed. Quantitative real-time polymerase chain reaction (PCR) was performed to detect FHL1 mRNA expression in 15 paired human lung cancer tissues and their adjacent normal lung tissues, or lung cancer cell lines (A549 and H1299) in comparison with human bronchial epithelial cell line (Beas- 2B). Moreover, western blot was used to analyze FHL1 and rho GDP-dissociation inhibitor beta (RhoGDIβ) protein expression in the indicated cell lines. Also, transwell assays were employed to measure the migrated, and invaded of indicated cell lines.
Results: FHL1 transcripts were downregulated in the human lung adenocarcinoma. The impaired FHL1 transcripts were positively correlated with advanced tumor node metastasis (TNM) stage. Moreover, as compared to the adjacent normal lung tissues, FHL1 mRNA was low expressed in 15 paired human lung cancer tissues than their adjacent normal lung tissues. Besides, FHL1 mRNA and protein expression were also reduced in H1299 and A549 cell lines in comparison with Beas-2B cell line. Overexpressed FHL1 protein inhibited the invasive ability of H1299 and A549 cell lines. Mechanically, FHL1 protein overexpression increased the RhoGDIβ protein and mRNA abundance, while knockdown of RhoGDIβ protein, completely restored the invasion ability of A549 (Flag-FHL1) cell line.
Conclusion: Our findings indicated that as a key FHL1 downstream regulator, RhoGDIβ is in charge of FHL1 inhibiting lung cancer cell invasion abilities, providing a critical insight into understanding the role of FHL1 for lung cancer development.


  1. Awad R,Nott L. Radiation recall pneumonitis induced by erlotinib after palliative thoracic radiotherapy for lung cancer: Case report and literature review. Asia Pac J Clin Oncol. 2016; 12(1): 91-95.
  2. Tang F, Tang S, Guo X, Yang C,Jia K. CT45A1 siRNA silencing suppresses the proliferation, metastasis and invasion of lung cancer cells by downregulating the ERK/CREB signaling pathway. Mol Med Rep. 2017; 16(5): 6708-6714.
  3. Herbst R S, Morgensztern D,Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018; 553(7689): 446- 454.
  4. Chu P H, Ruiz-Lozano P, Zhou Q, Cai C,Chen J. Expression patterns of FHL/SLIM family members suggest important functional roles in skeletal muscle and cardiovascular system. Mech Dev. 2000; 95(1-2): 259-265.
  5. Kadrmas J L,Beckerle M C. The LIM domain: from the cytoskeleton to the nucleus. Nat Rev Mol Cell Biol. 2004; 5(11): 920-931.
  6. Niu C, Liang C, Guo J, Cheng L, Zhang H, Qin X, et al. Downregulation and growth inhibitory role of FHL1 in lung cancer. Int J Cancer. 2012; 130(11): 2549-2556.
  7. Ding L, Wang Z, Yan J, Yang X, Liu A, Qiu W, et al. Human fourand- a-half LIM family members suppress tumor cell growth through a TGF-beta-like signaling pathway. J Clin Invest. 2009; 119(2): 349- 361.
  8. Ding L, Niu C, Zheng Y, Xiong Z, Liu Y, Lin J, et al. FHL1 interacts with oestrogen receptors and regulates breast cancer cell growth. J Cell Mol Med. 2011; 15(1): 72-85.
  9. Xu Y, Liu Z,Guo K. Expression of FHL1 in gastric cancer tissue and its correlation with the invasion and metastasis of gastric cancer. Mol Cell Biochem. 2012; 363(1-2): 93-99.
  10. Li X, Jia Z, Shen Y, Ichikawa H, Jarvik J, Nagele R G, et al. Coordinate suppression of Sdpr and Fhl1 expression in tumors of the breast, kidney, and prostate. Cancer Sci. 2008; 99(7): 1326-1333.
  11. Wang X, Wei X, Yuan Y, Sun Q, Zhan J, Zhang J, et al. Src-mediated phosphorylation converts FHL1 from tumor suppressor to tumor promoter. J Cell Biol. 2018; 217(4): 1335-1351.
  12. DerMardirossian C,Bokoch G M. GDIs: central regulatory molecules in Rho GTPase activation. Trends Cell Biol. 2005; 15(7): 356-363.
  13. Moissoglu K, McRoberts K S, Meier J A, Theodorescu D,Schwartz M A. Rho GDP dissociation inhibitor 2 suppresses metastasis via unconventional regulation of RhoGTPases. Cancer Res. 2009; 69(7): 2838-2844.
  14. Simons P, Bondu V, Wandinger-Ness A,Buranda T. Small-volume flow cytometry-based multiplex analysis of the activity of small GTPases. Methods Mol Biol. 2018; 1821: 177-195.
  15. Liu S, Cui H, Li Q, Zhang L, Na Q,Liu C. RhoGDI2 is expressed in human trophoblasts and involved in their migration by inhibiting the activation of RAC1. Biol Reprod. 2014; 90(4): 88.
  16. Niu H, Li H, Xu C,He P. Expression profile of RhoGDI2 in lung cancers and role of RhoGDI2 in lung cancer metastasis. Oncol Rep. 2010; 24(2): 465-471.
  17. Said N, Sanchez-Carbayo M, Smith SC,Theodorescu D. RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration. J Clin Invest. 2012; 122(4): 1503-1518.
  18. Zhu J, Tian Z, Li Y, Hua X, Zhang D, Li J, et al. ATG7 promotes bladder cancer invasion via autophagy-mediated increased ARHGDIB mRNA stability. Adv Sci (Weinh). 2019; 6(8): 1801927.
  19. Griner EM, Dancik GM, Costello JC, Owens C, Guin S, Edwards MG, et al. RhoC is an unexpected target of rhogdi2 in prevention of lung colonization of bladder cancer. Mol Cancer Res. 2015; 13(3): 483-492.
  20. Taylor SC, Posch A. The design of a quantitative western blot experiment. Biomed Res Int. 2014; 2014: 361590.
  21. Zhu J, Li Y, Chen C, Ma J, Sun W, Tian Z, et al. NF-kappaB p65 overexpression promotes bladder cancer cell migration via fbw7- mediated degradation of rhogdialpha protein. Neoplasia. 2017; 19(9): 672-683.
  22. Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017; 19(8): 649-658.
  23. Asada K, Ando T, Niwa T, Nanjo S, Watanabe N, Okochi-Takada E, et al. FHL1 on chromosome X is a single-hit gastrointestinal tumorsuppressor gene and contributes to the formation of an epigenetic field defect. Oncogene. 2013; 32(17): 2140-2149.
  24. Hubbi ME, Gilkes DM, Baek JH, Semenza GL. Four-and-a-half LIM domain proteins inhibit transactivation by hypoxia-inducible factor 1. J Biol Chem. 2012; 287(9): 6139-6149.
  25. Zhang S, Zheng C, Yao S, Wang Z, Xu L, Yang R, et al. Proteomic analysis of human prostate cancer PC-3M-1E8 cells and PC-3M- 2B4 cells of same origin but with different metastatic potential. PLoS One. 2018; 13(10): e0206139.
  26. Wang J, Huang F, Huang J, Kong J, Liu S,Jin J. Epigenetic analysis of FHL1 tumor suppressor gene in human liver cancer. Oncol Lett. 2017; 14(5): 6109-6116.
  27. Zhou L, Ding L, Liu J, Zhang Y, Luo X, Zhao L, et al. Four-and-ahalf LIM protein 1 promotes paclitaxel resistance in hepatic carcinoma cells through the regulation of caspase-3 activation. J Cancer Res Ther. 2018; 14 Supplement: S767-S773.
  28. Sun L, Chen L, Zhu H, Li Y, Chen C C,Li M. FHL1 promotes glioblastoma aggressiveness through regulating EGFR expression. FEBS Lett. 2021; 595(1): 85-98.
  29. Martin TA, Ye L, Sanders AJ, Lane J, Jiang WG. Cancer invasion and metastasis: molecular and cellular perspective. 2013. Available from: https://www.ncbi.nlm.nih.gov/books/NBK164700/ (31 Mar 2021).
  30. Xu R, Dong Y, Wang L, Tao X, Sun A,Wei D. TAT-RhoGDI2, a novel tumor metastasis suppressor fusion protein: expression, purification and functional evaluation. Appl Microbiol Biotechnol. 2014; 98(23): 9633-9641.
  31. Huang H, Jin H, Zhao H, Wang J, Li X, Yan H, et al. RhoGDIbeta promotes Sp1/MMP-2 expression and bladder cancer invasion through perturbing miR-200c-targeted JNK2 protein translation. Mol Oncol. 2017; 11(11): 1579-1594.
  32. Stevens EV, Banet N, Onesto C, Plachco A, Alan JK, Nikolaishvili- Feinberg N, et al. RhoGDI2 antagonizes ovarian carcinoma growth, invasion and metastasis. Small GTPases. 2011; 2(4): 202- 210.
  33. Niu H, Wu B, Jiang H, Li H, Zhang Y, Peng Y, et al. Mechanisms of RhoGDI2 mediated lung cancer epithelial-mesenchymal transition suppression. Cell Physiol Biochem. 2014; 34(6): 2007-2016.
  34. Niu H, Wu B, Peng Y, Jiang H, Zhang Y, Wang J, et al. RNA interference- mediated knockdown of RhoGDI2 induces the migration and invasion of human lung cancer A549 cells via activating the PI3K/Akt pathway. Tumour Biol. 2015; 36(1): 409-419.